Related Experiment Video
Updated: Jun 4, 2026
Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
Published on: May 1, 2019
PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues
Liang-ming Liu1, Ming-guo Yan, Dao-hua Yang
1Songjiang Hospital Affiliated to The First People's Hospital Shanghai Jiaotong University, Shanghai 201600, China. liuliangming@hotmail.com
Objective:
PIAS3 is the endogenous inhibitor of STAT3, which has been implicated in the pathogenesis of many cancers. However, the effect of PIAS3 on human tumors remains elusive. The aim of this article is to investigate the expression of PIAS3 in gastric carcinoma and its adjacent non-tumor tissues.
Methods:
Samples were taken from 30 patients with gastric cancer, which included tumor or non-tumor tissues in the excised sections. The expression of PIAS3 protein was detected by immunocytochemistry, and that of mRNA by in situ hybridization. The results were semi-quantitative analyzed by using cell count and color depth to stage.
Results:
The expression levels of PIAS3 protein and mRNA were significantly lower in gastric cancerous tissues than in its adjacent non-tumor tissues, and had a close relation with tumor size and differentiation, but not with age, gender and lymphatic metastasis in gastric carcinoma. The more large in size and poorly in differentiation, the more low PIAS3 expression was.
Conclusion:
Loss of PIAS3 expression may be an important characteristic of gastric cancer and suggest vicious degree of the tumor.
Insights
Loss of PIAS3 expression is significantly lower in gastric cancer tissues compared to non-tumor tissues. This reduced PIAS3 indicates a more aggressive tumor, suggesting its role in gastric carcinoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Signal transducer and activator of transcription 3 (STAT3) is involved in cancer pathogenesis.
- PIAS3 acts as an endogenous inhibitor of STAT3.
- The role of PIAS3 in human tumors, specifically gastric carcinoma, requires further investigation.
Purpose of the Study:
- To investigate the expression levels of PIAS3 in gastric carcinoma tissues.
- To compare PIAS3 expression in tumor tissues versus adjacent non-tumor tissues.
- To correlate PIAS3 expression with clinicopathological features of gastric cancer.
Main Methods:
- Immunocytochemistry was used to detect PIAS3 protein expression.
- In situ hybridization was employed to assess PIAS3 mRNA levels.
- Samples from 30 gastric cancer patients, including tumor and adjacent non-tumor tissues, were analyzed.
Main Results:
- PIAS3 protein and mRNA expression levels were significantly lower in gastric cancerous tissues compared to adjacent non-tumor tissues.
- Lower PIAS3 expression correlated with larger tumor size and poorer differentiation.
- No significant association was found between PIAS3 expression and patient age, gender, or lymphatic metastasis.
Conclusions:
- Reduced PIAS3 expression is a potential hallmark of gastric cancer.
- Loss of PIAS3 may serve as an indicator of tumor aggressiveness and poor prognosis in gastric carcinoma.
Related Concept Videos
01:26Gastritis II: Pathophysiology
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.